Can Ceftazidime and Ampicillin Be Given Together?
Yes, ceftazidime and ampicillin can be safely administered together, and this combination is specifically recommended in multiple clinical guidelines, particularly for neonatal sepsis, intra-abdominal infections in children, and certain gram-negative infections requiring enterococcal coverage.
Evidence-Based Recommendations
Pediatric/Neonatal Infections
The combination of ampicillin + ceftazidime is explicitly recommended by major guidelines:
For febrile infants 8-21 days old: Ampicillin IV/IM (150 mg/kg/day divided every 8h) + ceftazidime IV/IM (150 mg/kg/day divided every 8h) is the standard empiric regimen for UTI, suspected bacteremia, and bacterial meningitis 1
For bacterial meningitis in infants 22-28 days old: Ampicillin IV/IM (300 mg/kg/day divided every 6h) + ceftazidime IV/IM (150 mg/kg/day divided every 8h) remains recommended 1
For neonatal sepsis: A large multicenter trial of 1,316 neonates demonstrated that ceftazidime + ampicillin achieved a 97% cure rate in proven infections, significantly superior to aminoglycoside-based regimens (66%, p<0.002) 2
Intra-Abdominal Infections in Children
For community-acquired intra-abdominal infections in pediatric patients, guidelines from the Surgical Infection Society and IDSA recommend advanced-generation cephalosporins (including ceftazidime) together with metronidazole as acceptable regimens 3. The 2024 WHO guidelines note that ampicillin is specifically added to cephalosporin regimens to provide enterococcal coverage when the primary regimen would otherwise miss this pathogen 4.
Pharmacokinetic Considerations
CSF Penetration Data
Research demonstrates that ceftazidime does NOT significantly affect ampicillin levels when given together:
In rabbit meningitis models, simultaneous administration of ceftazidime with ampicillin showed no significant difference in ceftazidime CSF levels compared to ceftazidime alone 5
However, ampicillin CSF penetration decreased when combined with ceftazidime (from 8.81% to 2.77%), though this did not translate to clinical failures 5
In neonates, ampicillin CSF concentrations ranged from 1-80 mg/L when combined with ceftazidime—sufficient for treating enterococci and Listeria monocytogenes 6
Clinical Efficacy Maintained
Despite theoretical pharmacokinetic interactions, clinical outcomes remain excellent. The European neonatal sepsis study showed treatment success in >94% of patients across all regimens, with the ceftazidime + ampicillin combination demonstrating superior efficacy 2.
Microbiological Coverage Rationale
This combination provides complementary coverage:
- Ceftazidime: Excellent gram-negative coverage including Pseudomonas aeruginosa, Enterobacter, E. coli, Klebsiella
- Ampicillin: Covers enterococci, Listeria monocytogenes, and Group B Streptococcus
The 2024 WHO guidelines explicitly state: "Ampicillin was added to offer additional enterococcal coverage if the used regimen (e.g., ceftriaxone-metronidazole) would otherwise not cover enterococcus" 4.
Important Caveats
Drug Interaction Monitoring
The FDA label for ceftazidime notes that nephrotoxicity has been reported with concomitant cephalosporin and aminoglycoside use, requiring careful renal function monitoring 7. However, this concern does not apply to the ampicillin combination.
Avoid Chloramphenicol
Do not combine ceftazidime with chloramphenicol—in vitro antagonism has been demonstrated, and this combination should be avoided when bactericidal activity is desired 7.
Resistance Considerations
While the 2024 WHO guidelines note that ceftazidime was excluded from adult empiric therapy recommendations (suitable for targeted therapy only) 4, it remains appropriate for pediatric empiric therapy and when combined with ampicillin for specific indications 1, 3.
Practical Administration
Both drugs can be administered:
- Intravenously or intramuscularly
- At the same time (different IV lines/sites)
- Without dose adjustment for the combination itself
- With standard dosing based on age, weight, and renal function
Monitor for:
- Renal function (both drugs renally cleared)
- Clinical response within 48-72 hours
- Potential for Clostridioides difficile infection (as with any broad-spectrum regimen)